organization · Reporting owner
HBM Healthcare Investments (Cayman) Ltd.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nabriva Therapeutics Legacy plcNBRV · Entity 174291 | 10% owner | July 19, 2017 | July 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nabriva Therapeutics Legacy plc
Report date July 19, 2017 · Filed July 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,397,922 |
Ending reported balance
After 2017-07-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-07-19 · Sale · Disposed 20,786 · Balance 2,421,367 Row 2 · 2017-07-20 · Sale · Disposed 23,445 · Balance 2,397,922 |
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IO Biotech, Inc.
Report date November 09, 2021 · Filed November 12, 2021
Section 16 reporting ended · disclosed 2021-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,690,545 |
Ending reported balance
After 2021-11-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-09 · Conversion · Acquired 2,365,545 · Balance 2,365,545 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Row 2 · 2021-11-09 · Purchase · Acquired 325,000 · Balance 2,690,545 |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Conversion · Disposed 188,168 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
Mineralys Therapeutics, Inc.
Report date February 14, 2023 · Filed February 17, 2023
Section 16 reporting ended · disclosed 2023-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,218,106 |
Ending reported balance
After 2023-02-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-02-14 · Conversion · Acquired 1,941,368 · Balance 1,941,368 F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. Row 2 · 2023-02-14 · Conversion · Acquired 964,238 · Balance 2,905,606 F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. Row 3 · 2023-02-14 · Purchase · Acquired 312,500 · Balance 3,218,106 |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-02-14 · Conversion · Disposed 20,962,895 · Balance 0 F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-02-14 · Conversion · Disposed 10,411,846 · Balance 0 F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.
F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.
Nabriva Therapeutics plc
Report date September 12, 2017 · Filed September 15, 2017
Section 16 reporting ended · disclosed 2017-09-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,360,278 |
Reported balance
After 2017-09-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-12 · Sale · Disposed 10,458 · Balance 2,360,278 F1: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. F2: The balance was adjusted by one (1) share to account for a mathematical error in a prior filing. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,337,557 |
Reported balance
After 2017-09-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-09-13 · Sale · Disposed 22,721 · Balance 2,337,557 F3: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price |
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,334,128 |
Reported balance
After 2017-09-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-09-14 · Sale · Disposed 3,429 · Balance 2,334,128 F4: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
F2: The balance was adjusted by one (1) share to account for a mathematical error in a prior filing.
F3: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price
F4: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
Werewolf Therapeutics, Inc.
Report date May 04, 2021 · Filed May 05, 2021
Section 16 reporting ended · disclosed 2021-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 625,995 |
Reported balance
After 2021-05-04 transaction · row 1
1 source rowRow 1 · 2021-05-04 · Conversion · Acquired 625,995 · Balance 625,995 F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-04 · Conversion · Acquired 5,426,819 · Balance 0 F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2017 Filed Apr 11, 2017 10:04 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 18,001 | $10.96 | $197,290.96 |
DisclosureSEC source: 0001104659-17-022745 · a4a.xml · nonDerivative · entry 4 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707,162 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The prices reported in Column 4 are weighted average prices. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 10:04 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 3,500 | $11.04 | $38,640.00 |
DisclosureSEC source: 0001104659-17-022745 · a4a.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,725,163 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The prices reported in Column 4 are weighted average prices. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 01:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleCommon Shares | 24,600 | $11.20 | $275,520.00 |
DisclosureSEC source: 0001179110-17-005914 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,771 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 01:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleCommon Shares | 6,617 | $11.28 | $74,639.76 |
DisclosureSEC source: 0001179110-17-005914 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,371 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 10:04 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 24,600 | $11.20 | $275,520.00 |
DisclosureSEC source: 0001104659-17-022745 · a4a.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,728,663 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The prices reported in Column 4 are weighted average prices. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 10:04 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 6,617 | $11.28 | $74,639.76 |
DisclosureSEC source: 0001104659-17-022745 · a4a.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753,263 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The prices reported in Column 4 are weighted average prices. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.